drugset / Trial / NCT00792688

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

NCT00792688

Phase 2 Completed 26 enrolled TR Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

Timeline

Start
2008-10
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject beta-glucan Other / unclassified 0.1 % Topical
Subject beta-glucan Other / unclassified 1 % Topical

Indications

No indication recorded.